Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vitreoscilla filiformis emollient
- Development stage
- Unknown
- Lead developer
- L'Oréal
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
Vitreoscilla filiformis emollient refers to topical skin care products containing lysate or extract from the bacterium Vitreoscilla filiformis. These preparations are considered non-replicative probiotic fractions and are used as industrial raw materials in many cosmetic and dermatological formulations[1][3]. The mechanism of action is thought to mimic that of probiotics in the gut—regulating immunity, protecting and repairing the skin barrier, modulating inflammation, stimulating innate cutaneous defenses (including antioxidant and antimicrobial pathways), rebalancing the skin microbiome (notably by reducing Staphylococcus aureus overgrowth), and improving symptoms of inflammatory skin diseases such as atopic dermatitis[1][2][3][4]. Clinical studies have shown that these emollients can reduce pruritus, erythema, dryness, inflammatory lesions, improve sleep quality and daily discomfort in patients with atopic dermatitis or sensitive/dry skin[5][6]. The active ingredient is often referred to as Aqua Posae Filiformis (APF) when grown on thermal spring water-enriched medium[3][4].
- Brand names
- Life Plankton
- Other names
- Vitreoscilla filiformis extractAqua Posae FiliformisVfeAPF
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Vitreoscilla filiformis emollient.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vitreoscilla filiformis emollient.